Baseline characteristics of study patients on date of nearest quarter following marketplace introduction of infliximab
| Crohn’s disease (on 1 July 2001) | UC (on 1 April 2006) | |||
| Al patients n=21 561 | Publicly funded infliximab users n=1743 | All patients n=27 602 | Publicly funded infliximab users n=585 | |
| Age—median (IQR) | 41 (32–53) | 36 (27–47) | 48 (38–61) | 42 (28–57) |
| Sex | ||||
| % Male | 43.4 | 46.5 | 50.3 | 56.9 |
| % Female | 56.6 | 53.5 | 49.7 | 43.1 |
| Income quintile | ||||
| % Q1 | 16.8 | 20.6 | 15.5 | 16.8 |
| % Q2 | 19.9 | 20.6 | 18.5 | 20.0 |
| % Q3 | 20.5 | 20.5 | 20.3 | 20.0 |
| % Q4 | 20.4 | 18.0 | 21.9 | 20.7 |
| % Q4 | 22.0 | 19.3 | 23.4 | 21.4 |
| Unknown | 0.5 | 1.1 | 0.4 | 1.2 |
| Residential setting | ||||
| % Rural | 13.2 | 15.3 | 12.4 | 11.6 |
| % Urban | 86.4 | 83.6 | 87.3 | 87.5 |
| % Unknown | 0.3 | 1.0 | 0.2 | 0.9 |